Mangalam Drugs (India) Buy Hold or Sell Recommendation
| MANGALAM | 106.02 1.00 0.95% |
Assuming the 90 days trading horizon and your slightly conservative level of risk, our recommendation regarding Mangalam Drugs And is 'Strong Sell'. Macroaxis provides Mangalam Drugs buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MANGALAM positions.
Check out Mangalam Drugs Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Mangalam and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Mangalam Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Mangalam |
Execute Mangalam Drugs Buy or Sell Advice
The Mangalam recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Mangalam Drugs And. Macroaxis does not own or have any residual interests in Mangalam Drugs And or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Mangalam Drugs' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Mangalam Drugs Trading Alerts and Improvement Suggestions
| Mangalam Drugs And generated a negative expected return over the last 90 days | |
| The company reported the revenue of 3.67 B. Net Loss for the year was (90.72 M) with profit before overhead, payroll, taxes, and interest of 1.17 B. | |
| About 55.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Additional Considerations Required While Assessing Mangalam Drugs Organics Strong Earnings - Simply Wall St |
Mangalam Drugs Returns Distribution Density
The distribution of Mangalam Drugs' historical returns is an attempt to chart the uncertainty of Mangalam Drugs' future price movements. The chart of the probability distribution of Mangalam Drugs daily returns describes the distribution of returns around its average expected value. We use Mangalam Drugs And price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Mangalam Drugs returns is essential to provide solid investment advice for Mangalam Drugs.
| Mean Return | -0.24 | Value At Risk | -4.22 | Potential Upside | 3.87 | Standard Deviation | 2.24 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Mangalam Drugs historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Mangalam Drugs Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Mangalam Drugs or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Mangalam Drugs' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Mangalam stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.29 | |
β | Beta against Dow Jones | 0.31 | |
σ | Overall volatility | 2.03 | |
Ir | Information ratio | -0.16 |
Mangalam Drugs Volatility Alert
Mangalam Drugs And exhibits very low volatility with skewness of 0.09 and kurtosis of 0.79. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mangalam Drugs' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mangalam Drugs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Mangalam Drugs Fundamentals Vs Peers
Comparing Mangalam Drugs' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Mangalam Drugs' direct or indirect competition across all of the common fundamentals between Mangalam Drugs and the related equities. This way, we can detect undervalued stocks with similar characteristics as Mangalam Drugs or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Mangalam Drugs' fundamental indicators could also be used in its relative valuation, which is a method of valuing Mangalam Drugs by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Mangalam Drugs to competition |
| Fundamentals | Mangalam Drugs | Peer Average |
| Return On Equity | -0.0631 | -0.31 |
| Return On Asset | 0.005 | -0.14 |
| Profit Margin | 0.01 % | (1.27) % |
| Operating Margin | 0.06 % | (5.51) % |
| Current Valuation | 2.75 B | 16.62 B |
| Shares Outstanding | 15.83 M | 571.82 M |
| Shares Owned By Insiders | 54.58 % | 10.09 % |
| Price To Book | 1.22 X | 9.51 X |
| Price To Sales | 0.47 X | 11.42 X |
| Revenue | 3.67 B | 9.43 B |
| Gross Profit | 1.17 B | 27.38 B |
| EBITDA | 174.95 M | 3.9 B |
| Net Income | (90.72 M) | 570.98 M |
| Cash And Equivalents | 917.4 M | 2.7 B |
| Total Debt | 984.92 M | 5.32 B |
| Book Value Per Share | 85.79 X | 1.93 K |
| Cash Flow From Operations | 39.13 M | 971.22 M |
| Earnings Per Share | (4.03) X | 3.12 X |
| Number Of Employees | 432 | 18.84 K |
| Beta | 0.75 | -0.15 |
| Market Capitalization | 1.69 B | 19.03 B |
| Total Asset | 3.34 B | 29.47 B |
| Retained Earnings | 975.89 M | 9.33 B |
| Working Capital | 119.39 M | 1.48 B |
| Net Asset | 3.34 B |
Mangalam Drugs Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Mangalam . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 507.98 | |||
| Daily Balance Of Power | 0.2786 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 107.06 | |||
| Day Typical Price | 106.71 | |||
| Market Facilitation Index | 2.0E-4 | |||
| Price Action Indicator | (0.54) | |||
| Period Momentum Indicator | 1.0 |
About Mangalam Drugs Buy or Sell Advice
When is the right time to buy or sell Mangalam Drugs And? Buying financial instruments such as Mangalam Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Mangalam Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Mangalam Stock
Mangalam Drugs financial ratios help investors to determine whether Mangalam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mangalam with respect to the benefits of owning Mangalam Drugs security.